Last reviewed · How we verify
Bss (SODIUM CITRATE)
ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A prevents blood clotting by binding free calcium, a crucial co-factor in the clotting cascade.
At a glance
| Generic name | SODIUM CITRATE |
|---|---|
| Sponsor | B Braun |
| Drug class | sodium citrate |
| Target | Calcium |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1980 |
Mechanism of action
ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A works by binding free calcium in the blood, which is essential for several steps in the clotting process. By sequestering calcium, it prevents the formation of clots. The solution contains citric acid for pH regulation, sodium citrate for anticoagulation, and dextrose to maintain isotonicity.
Approved indications
- Platelet Rich Plasma (PRP) preparation
Common side effects
- Paraesthesia
- Feeling hot
- Pallor
- Hyperhidrosis
- Thirst
- Dizziness
- Nausea
- Dysgeusia
- Vision blurred
- Asthenia
- Dyspepsia
- Restlessness
Key clinical trials
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
- Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer (PHASE2)
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (PHASE3)
- A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) (PHASE2)
- Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bss CI brief — competitive landscape report
- Bss updates RSS · CI watch RSS
- B Braun portfolio CI